Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies.
This is a dose-response (DR) meta-analysis to evaluate the association of coffee consumption on endometrial cancer (EC) risk. A total 1,534,039 participants from 13 published articles were added in this meta-analysis. The RR of total coffee consumption and EC were 0.80 (95% CI: 0.74-0.86). A stronger association between coffee intake and EC incidence was found in patients who were never treated with hormones, 0.60 (95% CI: 0.50-0.72), and subjects with a BMI ≥25 kg/m(2), 0.57 (95% CI: 0.46-0.71). The overall RRs for caffeinated and decaffeinated coffee were 0.66 (95% CI: 0.52-0.84) and 0.77 (95% CI: 0.63-0.94), respectively. A linear DR relationship was seen in coffee, caffeinated coffee, decaffeinated coffee and caffeine intake. The EC risk decreased by 5% for every 1 cup per day of coffee intake, 7% for every 1 cup per day of caffeinated coffee intake, 4% for every 1 cup per day of decaffeinated intake of coffee, and 4% for every 100 mg of caffeine intake per day. In conclusion, coffee and intake of caffeine might significantly reduce the incidence of EC, and these effects may be modified by BMI and history of hormone therapy.
Department of Science and Education, First People's Hospital of Changde City, Changde 415003, Hunan, People's Republic of China.,
Changsha Center for Disease Control and Prevention, Changsha 410001, Hunan, People's Republic of China.,
Department of Oncology, First People's Hospital of Changde City, Changde 415003, Hunan, People's Republic of China.,
Department of Neurology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China.
Department of Oncology, Affiliated Hospital of Zunyi Medical University, Address: NO.149, Dalian Road, Zunyi City, Guizhou Province, China, 653000.
Hormone Replacement Therapy
Pub Type(s)Journal Article